Bleeding risk , Blood thinners and Esophageal dilation

Esophageal dilation is a procedure used to widen a narrowed esophagus, often performed using tools such as balloon dilators or Savary dilators. While the procedure itself is generally considered low risk, the bleeding risk can increase significantly in patients using blood thinners (anticoagulants or antiplatelet agents). Below is a detailed discussion of the bleeding risk associated with blood thinners during esophageal dilation, based on the provided context:

---

### **Key Findings on Bleeding Risk**

1. **Anticoagulant Use:**

• Patients on anticoagulants (e.g., warfarin, direct oral anticoagulants [DOACs] like rivaroxaban, dabigatran, apixaban, and edoxaban) had a **1.43-fold higher relative risk (RR)** of gastrointestinal (GI) bleeding within 30 days of esophageal dilation compared to nonusers.
• Among anticoagulants, **warfarin** posed the highest bleeding risk, with a **1.92-fold increase in bleeding risk**. This is likely due to warfarin's narrow therapeutic index and the challenges of maintaining its optimal therapeutic range.

2. **Dual Antiplatelet Therapy (DAPT):**

• Patients on DAPT (e.g., aspirin combined with ticagrelor, clopidogrel, or prasugrel) had numerically higher bleeding rates compared to nonusers or aspirin-only users. However, these differences did not reach statistical significance.
• This suggests that while DAPT increases bleeding risk, the absolute risk may not be as pronounced as with anticoagulants.

3. **Aspirin Alone:**

• Aspirin-only therapy was associated with a lower bleeding risk compared to DAPT, highlighting the additive bleeding risk when combining two antiplatelet agents.

4. **Timing of Antithrombotic Therapy Resumption:**

• Whether anticoagulant or antiplatelet therapy was resumed early or delayed after the procedure did not significantly alter the bleeding risk.

---

### **Clinical Implications**

1. **Guideline Recommendations:**

• Current guidelines recommend discontinuing anticoagulants before esophageal dilation to minimize bleeding risk, provided it is safe to do so. This is particularly important for patients on warfarin due to its higher risk profile.

2. **Thromboembolic vs. Bleeding Risk:**

• For patients on blood thinners, clinicians must balance the risk of thromboembolic events (e.g., stroke or clot formation) against the risk of bleeding. This decision requires a personalized approach, often involving collaboration with cardiology or hematology specialists.

3. **Warfarin-Specific Considerations:**

• Warfarin users represent a particularly high-risk group for postprocedural bleeding. These patients may require more cautious periprocedural planning, including temporary bridging with shorter-acting anticoagulants or careful INR (International Normalized Ratio) monitoring.

4. **Clinical Consequences of Bleeding:**

• Postprocedural bleeding in anticoagulated patients was associated with significant clinical consequences, including higher rates of blood transfusions, ICU admissions, and even mortality. This underscores the importance of optimizing antithrombotic management before esophageal dilation.

---

### **Summary of Practice Implications**

• **Anticoagulants:**
• Discontinuation before esophageal dilation is generally recommended to reduce bleeding risk.
• Warfarin users require extra caution due to their higher bleeding risk.
• DOAC users may have a slightly lower bleeding risk compared to warfarin, but individual risk factors must still be considered.

• **DAPT and Aspirin:**
• DAPT increases the bleeding risk compared to aspirin alone, but the absolute risk may not always be statistically significant.
• Aspirin-only therapy carries a relatively lower bleeding risk, making it a safer option in certain cases.

• **Multidisciplinary Collaboration:**
• Endoscopists should work closely with cardiologists and hematologists to individualize management strategies, especially for high-risk patients.

• **Postprocedural Monitoring:**
• Patients on anticoagulants or antiplatelets undergoing esophageal dilation should be closely monitored for signs of bleeding, given the potential for serious complications such as transfusion requirements, ICU admission, and mortality.

---

### **Conclusion**

Anticoagulant use, particularly warfarin, significantly increases the risk of post-esophageal dilation bleeding. Dual antiplatelet therapy also poses a higher bleeding risk compared to aspirin alone, though the differences may not always be statistically significant. Clinicians must carefully weigh the bleeding risk against the thromboembolic risk when managing blood thinners in patients undergoing esophageal dilation, emphasizing guideline-based discontinuation of therapy whenever safely feasible. Close monitoring and individualized care are critical to optimizing outcomes.